**WHAT IS CLAIMED IS:**

1. A compound of formula I



(I)

wherein

A is C, $CR_{10}$ or N;

X is $CR_{11}$ or N;

Y is $CR_7$ or N with the proviso that when X is N, then Y must be $CR_7$;

$R_1$ is H, $C_1$-$C_6$alkylcarbonyl, $C_1$-$C_6$alkylcarbonyloxy or an $C_1$-$C_6$alkyl, $C_1$-$C_6$alkenyl, $C_1$-$C_6$alkynl or cycloheteroalkyl group each optionally substituted;

$R_2$, $R_3$, $R_4$, $R_5$ and $R_6$ are each independently H, halogen, OH or an optionally substituted $C_1$-$C_6$alkyl group;

$R_7$ and $R_{11}$ are each independently H, halogen or an $C_1$-$C_6$alkyl, aryl, heteroaryl or $C_1$-$C_6$alkoxy group each optionally substituted;

$R_8$ is an $C_1$-$C_6$alkyl, aryl or heteroaryl group each optionally substituted;

$R_9$ is H, halogen or an $C_1$-$C_6$alkyl, $C_1$-$C_6$alkoxy, $C_1$-$C_6$alkenyl, aryl or heteroaryl group each optionally substituted;

$R_{10}$ is H, OH or an optionally substituted $C_1$-$C_6$alkoxy group;
m is an integer of 1, 2 or 3;
n is 0 or an integer of 1, 2 or 3; and
---- represents a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein A is N and m is 2.

3. The compound according to claim 1 wherein $R_8$ is an optionally substituted phenyl group.

4. The compound according to claim 1 wherein $R_2$, $R_3$, $R_4$, $R_5$ and $R_6$ are H.

5. The compound according to claim 2 wherein $R_1$ is H or a $C_1$-$C_6$alkyl or cycloheteroalkyl group each optionally substituted.

6. The compound according to claim 5 selected from the group consisting of:
1-(phenylsulfonyl)-4-piperazin-1-yl-1H-indole;
1-[(2-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;
1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;
1-[(3,4-dimethoxyphenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;
1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;
1-[(4-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;
1-[(5-bromothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;
1-[(4,5-dichlorothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

methyl 4-[(4-piperazin-1-yl-1H-indol-1-yl)sulfonyl]phenyl ether;

4-piperazin-1-yl-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-(phenylsulfonyl)-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(2-bromophenyl)sulfonyl]-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indole;

4-[4-(3-methoxybenzyl)piperazin-1-yl]-1-(phenylsulfonyl)-1H-indole;

1-(phenylsulfonyl)-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1H-indole;

1-(phenylsulfonyl)-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(3-methoxybenzyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-indole;

1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;

1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;

1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;

1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;
1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;
1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;
1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-indazole;
1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-1H-indazole; and
the pharmaceutically acceptable salts thereof.

7. A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound of formula I.




(I)

wherein

A is C, $CR_{10}$ or N;

X is $CR_{11}$ or N;

Y is $CR_7$ or N with the proviso that when X is N, then Y must be $CR_7$;

$R_1$ is H, $C_1$-$C_6$alkylcarbonyl, $C_1$-$C_6$alkylcarbonyloxy or an $C_1$-$C_6$alkyl, $C_1$-$C_6$alkenyl, $C_1$-$C_6$alkynl or cycloheteroalkyl group each optionally substituted;

$R_2$, $R_3$, $R_4$, $R_5$ and $R_6$ are each independently H, halogen, OH or an optionally substituted $C_1$-$C_6$alkyl group;

$R_7$ and $R_{11}$ are each independently H, halogen or an $C_1$-$C_6$alkyl, aryl, heteroaryl or $C_1$-$C_6$alkoxy group each optionally substituted;

$R_8$ is an $C_1$-$C_6$alkyl, aryl or heteroaryl group each optionally substituted;

$R_9$ is H, halogen or an $C_1$-$C_6$alkyl, $C_1$-$C_6$alkoxy, $C_1$-$C_6$alkenyl, aryl or heteroaryl group each optionally substituted;

$R_{10}$ is H, OH or an optionally substituted $C_1$-$C_6$alkoxy group;

m is an integer of 1, 2 or 3;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or a pharmaceutically acceptable salt thereof.

8. The method according to claim 7 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.

9. The method according to claim 7 wherein said disorder is schizophrenia or depression.

10. The method according to claim 8 wherein said cognitive disorder is a neurodegenerative disorder.

11. The method according to claim 10 wherein said neurodegenerative disorder is Alzheimer's disease or Parkinson's disease

12. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I.



(I)

wherein

A is C, $CR_{10}$ or N;

X is $CR_{11}$ or N;

Y is $CR_7$ or N with the proviso that when X is N, then Y must be $CR_7$;

$R_1$ is H, $C_1$-$C_6$alkylcarbonyl, $C_1$-$C_6$alkylcarbonyloxy or an $C_1$-$C_6$alkyl, $C_1$-$C_6$alkenyl, $C_1$-$C_6$alkynl or cycloheteroalkyl group each optionally substituted;

$R_2$, $R_3$, $R_4$, $R_5$ and $R_6$ are each independently H, halogen, OH or an optionally substituted $C_1$-$C_6$alkyl group;

$R_7$ and $R_{11}$ are each independently H, halogen or an $C_1$-$C_6$alkyl, aryl, heteroaryl or $C_1$-$C_6$alkoxy group each optionally substituted;

$R_8$ is an $C_1$-$C_6$alkyl, aryl or heteroaryl group each optionally substituted;

$R_9$ is H, halogen or an $C_1$-$C_6$alkyl, $C_1$-$C_6$alkoxy, $C_1$-$C_6$alkenyl, aryl or heteroaryl group each optionally substituted;

$R_{10}$ is H, OH or an optionally substituted $C_1$-$C_6$alkoxy group;

m is an integer of 1, 2 or 3;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.

13. The composition according to claim 12 wherein A is N and m is 2.

14. The composition according to claim 12 wherein $R_8$ is an optionally substituted phenyl group.

15. The composition according to claim 12 wherein $R_2$, $R_3$, $R_4$, $R_5$ and $R_6$ are H.

16. The composition according to claim 13 wherein $R_1$ is H or a $C_1$-$C_6$alkyl or cycloheteroalkyl group each optionally substituted.

17. The composition according to claim 16 having a compound of formula I selected from the group consisting of:

1-(phenylsulfonyl)-4-piperazin-1-yl-1H-indole;

1-[(2-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(3,4-dimethoxyphenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(5-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(4-bromophenyl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(5-bromothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

1-[(4,5-dichlorothien-2-yl)sulfonyl]-4-piperazin-1-yl-1H-indole;

methyl 4-[(4-piperazin-1-yl-1H-indol-1-yl)sulfonyl]phenyl ether;

4-piperazin-1-yl-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}-1H-indole;

4-(4-benzylpiperazin-1-yl)-1-(phenylsulfonyl)-1H-indole;
4-(4-benzylpiperazin-1-yl)-1-[(2-bromophenyl)sulfonyl]-1H-indole;
4-(4-benzylpiperazin-1-yl)-1-[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indole;
4-(4-benzylpiperazin-1-yl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indole;
4-[4-(3-methoxybenzyl)piperazin-1-yl]-1-(phenylsulfonyl)-1H-indole;
1-(phenylsulfonyl)-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1H-indole;
1-(phenylsulfonyl)-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-indole;
1-[(2-bromophenyl)sulfonyl]-4-[4-(3-methoxybenzyl)piperazin-1-yl]-1H-indole;
1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-4-ylmethyl)piperazin-1-yl]-1H-indole;
1-[(2-bromophenyl)sulfonyl]-4-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-indole;
1-(phenylsulfonyl)-5-piperazin-1-yl-1H-indazole;
1-(phenylsulfonyl)-6-piperazin-1-yl-1H-indazole;
1-[(2-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
1-[(4-bromophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;
1-[(4-bromophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
1-[(5-bromothien-2-yl)sulfonyl]-5-piperazin-1-yl-1H-indazole;
1-[(5-bromothien-2-yl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
1-[(4-fluorophenyl)sulfonyl]-5-piperazin-1-yl-1H-indazole;
1-[(4-fluorophenyl)sulfonyl]-6-piperazin-1-yl-1H-indazole;
methyl 4-[(5-piperazin-1-yl-1H-indazol-1-yl)sulfonyl]phenyl ether;
1-phenylsulfonyl-4-(4-propylpiperazin-1-yl)-1H-indazole;

1-phenylsulfonyl-4-piperazin-1-yl-1H-indazole;
1-phenylsulfonyl-4-(4-phenethylpiperazin-1-yl)-1H-indazole;
1-phenylsulfonyl-4-[4-(3-phenylpropyl)-piperazin-1-yl]-1H-indazole; and
the pharmaceutically acceptable salts thereof.

18. A method for the preparation of a compound of formula I.



(I)

wherein
A is C, $CR_{10}$ or N;
X is $CR_{11}$ or N;
Y is $CR_7$ or N with the proviso that when X is N, then Y must be $CR_7$;
$R_1$ is $C_1$-$C_6$alkylcarbonyl, $C_1$-$C_6$alkylcarbonyloxy or an $C_1$-$C_6$alkyl, $C_1$-$C_6$alkenyl, $C_1$-$C_6$alkynl or cycloheteroalkyl group each optionally substituted;
$R_2$, $R_3$, $R_4$, $R_5$ and $R_6$ are each independently H, halogen, OH or an optionally substituted $C_1$-$C_6$alkyl group;
$R_7$ and $R_{11}$ are each independently H, halogen or an $C_1$-$C_6$alkyl, aryl, heteroaryl or alkoxy group each optionally substituted;
$R_8$ is an $C_1$-$C_6$alkyl, aryl or heteroaryl group each optionally substituted;

$R_9$ is H, halogen or an $C_1$-$C_6$alkyl, $C_1$-$C_6$alkoxy, $C_1$-$C_6$alkenyl, aryl or heteroaryl group each optionally substituted;

$R_{10}$ is H, OH or an optionally substituted $C_1$-$C_6$alkoxy group;

m is an integer of 1, 2 or 3;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond

said method which comprises reacting a compound of formula Ia




(Ia)

wherein A, X, $R_2$, $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, m and n are as defined hereinabove for formula I with a compound $R_1$-Hal wherein $R_1$ is as defined hereinabove for formula I and Hal is Cl, Br or I.